TLX Stock Analysis: Buy, Sell, or Hold?
TLX - Telix Pharmaceuticals Limited American Depositary Shares
$10.97
-0.17 (-1.53%)
▼
5d:
-9.71%
30d:
+16.21%
90d:
+4.08%
HOLD
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jul 02, 2026
0d
Get Alerted When TLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TLX trades at premium valuation expecting 8.4% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: TLX trades at premium valuation expecting 8.4% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.86
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$9.85
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TLX is currently trading at $10.97, which is considered fair relative to its 30-day fair value range of $9.56 to $11.49. From a valuation perspective, the stock is trading at a premium (Forward PE: 33.7) compared to its historical average (26.4). At these levels, the market is pricing in 8.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TLX is in a strong downtrend. The price is currently testing key support at $10.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.84 (+90.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TLX is in a strong downtrend. The price is currently testing key support at $10.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.84 (+90.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$9.56 -
$11.49
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 90.0% below Wall St target ($20.84)
- NEUTRAL: Trading at premium valuation - market expects 8.4% growth which is achievable
- CAUTION: Recommendation downgraded due to -9.7% 5-day decline
Trading Range Analysis
30-Day Trading Range
$9.56 -
$11.49
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$10.95
Resistance Level
$12.23
Current Trend
Strong Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
33.67
Wall Street Target
$20.84
(+90.0%)
Revenue Growth (YoY)
49.3%
Profit Margin
-0.9%
Valuation Premium vs History
+8.4% premium
PE vs Historical
33.7 vs 26.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.4%
(market-implied from PE analysis)
1-Year Target
$11.89
(+8%)
2-Year Target
$12.89
(+18%)
3-Year Target
$13.97
(+27%)
3-Yr Target (if PE normalizes)
(PE: 34→26)
PE COMPRESSION
$10.96
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 33.7, Growth: 157.3%)
$37.02
(+238%)
Base:
(SPY PE: 21.8, Growth: 157.3%)
$23.95
(+118%)
Bear:
(PE: 18.5, Growth: 157.3%)
$20.36
(+86%)
Share & Embed Analysis
Last updated: July 13, 2026 6:02 PM ET
Data refreshes hourly during market hours. Next update: 7:02 PM
Data refreshes hourly during market hours. Next update: 7:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 59 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 49 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 54 HOLD |
